Drug intelligence / Profile preview

lu ag06474

Development stage: Phase 1
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Lu AG06474 is an oral small molecule drug developed by Lundbeck for the treatment of pain and other nervous system diseases. It acts as a **monoacylglycerol lipase (MAGL) inhibitor**, targeting the MAGL enzyme to modulate endocannabinoid signaling pathways involved in pain processing and potentially other neurological or psychiatric disorders. The drug has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and analgesic properties in healthy volunteers[1][2][3][4][5][7]. As of late 2024, it remains in early-stage development with no approved indications.

Targets

MGLL (Monoacylglycerol lipase)

Beyond the preview

Go deeper on lu ag06474.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lu ag06474.

Explore the full profile